EyeGate Announces Completion of $11.25 Million Public Offering
17 avr. 2018 16h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Announces $11.25 Million Public Offering
13 avr. 2018 07h00 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Issued New Patent for Iontophoretic Contact Lens Technology
11 avr. 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., April 11, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Receives FDA Feedback on Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel
09 avr. 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis
06 avr. 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), today announced completion of patient enrollment for the pivotal Phase 3...
EyeGate Pharma To Participate At The 30TH Annual ROTH Conference
09 mars 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., March 09, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Pharma Submits Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel
08 mars 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update
02 mars 2018 16h28 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
EyeGate to Present at the 2018 BIO CEO & Investor Conference
07 févr. 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery
05 févr. 2018 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...